Selective Glucocorticoid Receptor Modulators (SGRMs) delay castrate-resistant prostate cancer growth

Jacob Kach, Tiha M. Long, Phillip Selman, Eva Y. Tonsing-Carter, Maria A. Bacalao, Ricardo R. Lastra, Larischa De Wet, Shane Comiskey, Marc Gillard, Calvin VanOpstall, Diana C. West, Wen Ching Chan, Donald Vander Griend, Suzanne D. Conzen, Russell Z. Szmulewitz

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

Increased glucocorticoid receptor (GR) expression and activity following androgen blockade can contribute to castration-resistant prostate cancer (CRPC) progression. Therefore, we hypothesized that GR antagonism will have therapeutic benefit in CRPC. However, the FDA-approved nonselective, steroidal GR antagonist, mifepristone, lacks GR specificity, reducing its therapeutic potential. Here, we report that two novel nonsteroidal and highly selective GR modulators (SGRM), CORT118335 and CORT108297, have the ability to block GR activity in prostate cancer and slow CRPC progression. In contrast to mifepristone, these novel SGRMs did not affect androgen receptor (AR) signaling, but potently inhibited GR transcriptional activity. Importantly, SGRMs decreased GR-mediated tumor cell viability following AR blockade. In vivo, SGRMs significantly inhibited CRPC progression in high GR–expressing, but not in low GR–expressing xenograft models. Transcriptome analysis following AR blockade and GR activation revealed that these SGRMs block GR-mediated proliferative gene expression pathways. Furthermore, GR-regulated proliferation-associated genes AKAP12, FKBP5, SGK1, CEBPD, and ZBTB16 are inhibited by CORT108297 treatment in vivo. Together, these data suggest that GR-selective nonsteroidal SGRMs potently inhibit GR activity and prostate cancer growth despite AR pathway inhibition, demonstrating the therapeutic potential of SGRMs in GR-expressing CRPC.

Original languageEnglish (US)
Pages (from-to)1680-1692
Number of pages13
JournalMolecular Cancer Therapeutics
Volume16
Issue number8
DOIs
StatePublished - Aug 2017

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Selective Glucocorticoid Receptor Modulators (SGRMs) delay castrate-resistant prostate cancer growth'. Together they form a unique fingerprint.

  • Cite this

    Kach, J., Long, T. M., Selman, P., Tonsing-Carter, E. Y., Bacalao, M. A., Lastra, R. R., De Wet, L., Comiskey, S., Gillard, M., VanOpstall, C., West, D. C., Chan, W. C., Vander Griend, D., Conzen, S. D., & Szmulewitz, R. Z. (2017). Selective Glucocorticoid Receptor Modulators (SGRMs) delay castrate-resistant prostate cancer growth. Molecular Cancer Therapeutics, 16(8), 1680-1692. https://doi.org/10.1158/1535-7163.MCT-16-0923